Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (10)

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2019

  1. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

2018

  1. Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (57-68), 10.1007/s12094-017-1783-2)

    Clinical and Translational Oncology

  2. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

  3. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 57-68

2017

  1. Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido

    Enfermedades Infecciosas y Microbiologia Clinica

2016

  1. Management of infection and febrile neutropenia in patients with solid cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 6, pp. 557-570

2015

  1. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 96, Núm. 2, pp. 308-318

2014

  1. Denosumab: Treatment efficacy in the control of metastatic bone disease

    Cancer and Chemotherapy Reviews, Vol. 9, Núm. 1, pp. 27-32

2012

  1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 83, Núm. 3, pp. 341-352